This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1…

Refractory Malignant Solid NeoplasmOsteosarcomaLeiomyosarcomas+4 more

~Estimated

~$10 – $6,250

City of Hope Medical CenterNCT05227326

Phase 2

A Non-Randomized, Open-label Phase II Trial Testing the Activity of XL092 (Zanzalintinib) in Patients With Advanced Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other pl…

Metastatic LeiomyosarcomaUnresectable LeiomyosarcomaBone Sarcoma+7 more

~Estimated

~$10 – $6,250

Northwestern UniversityNCT06571734